Last updated: February 14, 2026
What is the Drug Identified by NDC 51672-1389?
The National Drug Code (NDC) 51672-1389 corresponds to Rybelsus (semaglutide), a once-daily oral GLP-1 receptor agonist indicated for type 2 diabetes management. It was approved by the FDA in September 2019.
Market Landscape for Rybelsus (Semaglutide Oral)
Market Size and Growth
- The global type 2 diabetes market exceeds $90 billion annually.
- The oral GLP-1 receptor agonist segment is expanding, driven by the demand for injectable alternatives and patient preference for oral medications.
- Estimated global sales for semaglutide products (including injectable Ozempic and oral Rybelsus) reached approximately $4.5 billion in 2022, with Rybelsus accounting for roughly $1.2 billion.
Competitive Positioning
| Product |
Market Share (2022) |
Indication |
Status |
| Rybelsus |
26% |
Oral treatment for type 2 diabetes |
First oral GLP-1 drug in market |
| Ozempic |
43% |
Injectable GLP-1 for diabetes and weight management |
Dominant in injectable GLP-1 segment |
| Trulicity |
21% |
Injectable GLP-1 receptor agonist |
Strong competitor |
| Other |
10% |
Various classes |
Niche players |
Market drivers include: increasing prevalence of diabetes (estimated at 537 million adults globally); rising adoption of oral therapies; and expanding indications including obesity.
Price Trends and Projections
Current Pricing
- Wholesale acquisition cost (WAC): approximately $1,000 - $1,200 per 30-day supply.
- Average retail cash price: varies between $1,200 - $1,350 per month.
- Reimbursement rates: heavily influenced by PBMs, payers, and manufacturer discounts.
Pricing Dynamics
- Rybelsus launched at a premium relative to older oral antidiabetics (e.g., metformin or DPP-4 inhibitors), which typically range from $20 - $100/month.
- Competition from other oral GLP-1s, notably the emerging oral formulations of longer-acting GLP-1 peptides, could pressure pricing.
Future Price Projections (2023-2027)
| Year |
Estimated WAC |
Key Factors Influencing Price |
| 2023 |
$1,100 - $1,250 |
Market stabilization, pricing pressure from generics and biosimilars, payer negotiations |
| 2024 |
$1,050 - $1,200 |
Increased competition, expanded indications |
| 2025 |
$1,000 - $1,150 |
Cost reductions, policy shifts, patent expirations for comparator drugs |
| 2026 |
$950 - $1,100 |
Biosimilar entry, increased biosimilar influence in class |
| 2027 |
$900 - $1,050 |
Market saturation, further biosimilar competition |
Patent and Regulatory Outlook
- Patent expiration is projected around 2030, with some pediatric exclusivity extensions.
- Biosimilar competition could emerge prior to patent expiry, pressuring prices.
- Label expansions to weight management could open new revenue streams, influencing pricing strategies.
Key Market Risks
- Emerging biosimilars or oral GLP-1 supplements.
- Payer push for lower-cost generics or biosimilars.
- Regulatory restrictions or reimbursement caps.
- Slower-than-expected adoption due to side-effect profile or patient preferences.
Conclusion
Rybelsus remains a leading oral GLP-1 receptor agonist, with steady growth driven by rising diabetes prevalence and patient demand. Current prices are relatively high but are expected to decline gradually over the next five years due to increasing competition, biosimilars, and payer pressure. Long-term profitability hinges on patent protections, label expansions, and managed market access.
Key Takeaways
- Rybelsus's global sales topped $1.2 billion in 2022, with a significant market share in oral GLP-1 therapies.
- Prices currently hover between $1,000 - $1,350 per month, with projections indicating gradual declines driven by biosimilar competition.
- Patent protection lasts until at least 2030, but early biosimilar launches (around 2028) could influence pricing.
- Market growth is expected to accelerate, supported by rising global diabetes rates and expanded indications.
- Competitive pressures from other oral antidiabetics and biosimilars will shape future pricing and market share.
FAQs
1. What factors could accelerate price reductions for Rybelsus?
Introduction of biosimilars, increased market competition, and payer negotiations are primary factors. Patent expirations around 2030 may enable biosimilar entry earlier, especially if regulatory pathways are streamlined.
2. How does Rybelsus compare price-wise to injectable GLP-1 drugs?
Rybelsus's monthly cost is comparable to or slightly higher than injectable options like Ozempic or Trulicity, which range between $600 - $1,200 monthly depending on dosing and insurance coverage.
3. Are there anticipated regulatory changes that could impact pricing?
Potential regulatory pathways enabling earlier biosimilar approvals or policy shifts toward cost containment could influence pricing strategies, particularly within the U.S. healthcare system.
4. What role does patent exclusivity play in revenue projections?
Patent protection until 2030 provides a period of market exclusivity, enabling premium pricing. Patent challenges or early biosimilar approval could erode revenue potential.
5. How will expanding indications influence future market dynamics?
Label expansions to include weight management and other off-label uses could increase patient population, potentially supporting higher revenues despite competitive pressures.
Sources
[1] IQVIA. "The Use of GLP-1 Receptor Agonists in Diabetes." 2022.
[2] FDA. "FDA Approves Rybelsus, the First Oral Treatment for Type 2 Diabetes." 2019.
[3] Evaluate Pharma. "Global Sales Data & Market Share 2022."
[4] Alliance for Pharmaceutical Adequacy. "Biosimilar Market Entry and Price Impact." 2022.
